Navigation Links
New drug screening identifies chemical agents with potent anti-cancer activity
Date:1/5/2012

Drugs already approved for clinical use across a variety of therapeutic categories can be screened to identify effective agents for thyroid cancer according to a recent study accepted for publication in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM). These findings could rapidly be implemented into a clinical trial to test how effective the treatment would be.

The discovery of new chemical agents capable of modulating a disease is a long and expensive process. An alternative approach that is just beginning to be explored is the potential repurposing of already established drugs which have been approved for clinical use. The current study examined the newly assembled National Institutes of Health (NIH) Chemical Genomic Center's pharmaceutical collection, which contains 2,816 approved drugs and bioactive compounds and sought to identify agents with an anti-cancer effect in thyroid cancer cell lines.

"To our knowledge, this is the first study to use such a large collection of clinical drugs to test anti-proliferative effect in cancer cells," said Electron Kebebew, MD, of the National Cancer Institute in Bethesda, MD and lead author of the study. "The compounds found to have potent activity in our screen represent possible opportunities to repurpose these drugs for the treatment of patients with aggressive recurrent or metastatic thyroid cancer."

In this study, researchers used a quantitative high-throughput screening (qHTS) approach to examine the effect of 2,816 clinically approved drugs on thyroid cancer cells. qHTS is a titration-based screening paradigm where compounds are screened at multiple concentrations. By employing this approach, researchers found numerous agents across different therapeutic categories and mode of action that had an anti-cancer effect.

"Clinicians can more readily translate these findings into therapy when the drug characteristics are well-known. The drugs can then be used in developing clinical trials or in some cases for off-label use," said Kebebew. "Furthermore, qHTS could be used for identifying therapeutics not only for cancer, but for many other diseases."


'/>"/>
Contact: Aaron Lohr
alohr@endo-society.org
240-482-1380
The Endocrine Society
Source:Eurekalert

Related medicine news :

1. Self-affirmation may break down resistance to medical screening
2. Screening Alone Not Enough to Prevent Sudden Death in College Athletes
3. Making Sense of Cancer Screening Updates
4. IASLC sets up committee to move CT lung cancer strategic screening forward
5. American Cancer Society revises cancer screening guideline process
6. Biopsy referral after PSA screening stays consistent over time
7. NCAA mandatory sickle cell screening program not enough to save athletes lives
8. British Screening Program Finding More Early Stage Colon Cancers
9. Mammography screening reduced risk for death from breast cancer by half
10. Targeted Drugs, Lung CT Screening Top Cancer Advances in 2011
11. Studies of patients with cirrhosis uncover limitations in liver cancer screening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2016)... ... May 28, 2016 , ... SuperCloset is proud to officially launch our ... to day issues, struggles and obstacles veterans’ need to overcome in order to face ... active or retired military veteran(s) with a donated SuperCloset product based on the needs ...
(Date:5/28/2016)... ... ... After a year and a half of planning the Multiple Pathways of Recovery Conference ... of Recovery Conference was held May 2 -4, 2016 at the Mystic Marriott Hotel ... to explore the many pathways individuals use to get into and sustain their recovery. ...
(Date:5/27/2016)... ... ... Southland Log Homes , designer and manufacturer of America’s Favorite Log ... be found on its website at SouthlandLogHomes.com. , The designs of the wood ... craftsmanship of timber post and beam construction. The result is a barn that ...
(Date:5/27/2016)... ... May 27, 2016 , ... An influential resource amongst nurses and ... to shed lights on the variety of topics detailing why we appreciate nurses in ... why this career has gone from being in a major recession to one of ...
(Date:5/27/2016)... New York, NY (PRWEB) , ... May 27, ... ... caregivers to casual readers, this installment is bolstered by inspiring human-interest stories, courtesy ... trends and tech within the industry, from leading advocates, associations and industry leaders ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... 24, 2016 ARANZ Medical  Ltd ... healthcare sector, has been named the Coretex Hi-Tech Emerging Company ... Dr Bruce Davey , CEO of ARANZ ...  It,s really good to be recognised for the work we ... are used in 35 countries around the world from Sub-Saharan ...
(Date:5/24/2016)... 24, 2016 Celsion Corporation (NASDAQ: ... today provided an update on its ongoing OVATION ... combining GEN-1, the Company,s DNA-based immunotherapy, with the ... patients with advanced ovarian cancer who will undergo ... is an IL-12 DNA plasmid vector formulated as ...
(Date:5/24/2016)... KONG , May 24, 2016 ... , the world , s first ... AV fistula intervention   OrbusNeich, a global ... has expanded its portfolio to include products to treat ... are the company,s first entry devices for lower limb ...
Breaking Medicine Technology: